TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25605690

Group type: EXPERIMENTAL
Intervention: Voice rest and supplemental text‐to‐speech communication
Number of subjects: 37

Group type: COMPARATOR
Intervention: Voice rest alone
Number of subjects: 37
Study: 24089589

Group type: COMPARATOR
Intervention: Strength Training + Placebo
Number of subjects: 54

Group type: COMPARATOR
Intervention: Testosterone Treatment (TT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Strength Training + Testosterone Treatment (ST + TT)
Number of subjects: 54
Study: 21839579

Group type: EXPERIMENTAL
Intervention: Gemcitabine and paclitaxel (GP)
Number of subjects: 102
Study: 19250103

Group type: EXPERIMENTAL
Intervention: New pacing mode algorithm designed to minimize right ventricular (V) pacing
Number of subjects: 208

Group type: COMPARATOR
Intervention: DDD mode with a long atrioventricular (AV) delay
Number of subjects: 208
Study: 15841789

Group type: EXPERIMENTAL
Intervention: Lipid-lowering treatment
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Oral information
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Written and oral information
Number of subjects: 55
Study: 11271868

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Counselling
Number of subjects: 160
Study: 9924533

Group type: EXPERIMENTAL
Intervention: Single infusion of 5 mg/kg ABLC (Group A)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Two infusions of 5 mg/kg ABLC given 5 days apart (Group B)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Two infusions of 5 mg/kg ABLC on consecutive days (Group C)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Higher dose ABLC (10-15 mg/kg.day) for treatment failures
Number of subjects: 77

Group type: COMPARATOR
Intervention: Short-course ABLC (1-5 days)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Conventional amphotericin B (0.75-1.0 mg/kg on alternate days over 30-34 days)
Number of subjects: 77
Study: 30306284

Group type: EXPERIMENTAL
Intervention: 100% oxygen at 7 L/min
Number of subjects: 98

Group type: COMPARATOR
Intervention: 100% oxygen at 12 L/min
Number of subjects: 98
Study: 28073680

Group type: EXPERIMENTAL
Intervention: Simultaneous initiation of Vitamin B12 and Folate supplementation (within 24 hours of chemotherapy initiation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed initiation of Vitamin B12 and Folate supplementation (after 5-7 days of supplementation)
Number of subjects: 0
Study: 26196407

Group type: EXPERIMENTAL
Intervention: ARB/TZ combination therapy
Number of subjects: 87

Group type: COMPARATOR
Intervention: ARB/CCB combination therapy
Number of subjects: 87
Study: 24190245

Group type: EXPERIMENTAL
Intervention: Rasagiline
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 19194957

Group type: EXPERIMENTAL
Intervention: Postural management equipment used at recommended and moderate levels
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Postural management equipment
Number of subjects: 39
Study: 17307706

Group type: EXPERIMENTAL
Intervention: SSRIs (sertraline, citalopram, paroxetine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GABAergic agents (vigabatrin, tiagabine, topiramate, phenobarbitone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study: 15466722

Group type: EXPERIMENTAL
Intervention: Bone-patellar tendon-bone graft
Number of subjects: 120

Group type: COMPARATOR
Intervention: Doubled hamstring tendon graft
Number of subjects: 120
Study: 12365906

Group type: EXPERIMENTAL
Intervention: 0.03% bimatoprost QD
Number of subjects: 1198

Group type: EXPERIMENTAL
Intervention: 0.03% bimatoprost BID
Number of subjects: 1198

Group type: COMPARATOR
Intervention: 0.5% timolol BID
Number of subjects: 1198
Study: 9681342

Group type: EXPERIMENTAL
Intervention: Recombinant human interferon gamma, 50 microg/m2, daily subcutaneous injection
Number of subjects: 24
Study: 8595638

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 250 mg BID
Number of subjects: 360

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 500 mg TID
Number of subjects: 360
Study: 2548018

Group type: EXPERIMENTAL
Intervention: Endothelial cells from smokers after 15 minutes of collagenase exposure (group A)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Endothelial cells from smokers after 7 minutes of collagenase exposure (group B)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Endothelial cells from nonsmokers (group A)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Endothelial cells from nonsmokers (group B)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Endothelial cells from smokers (group A)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Endothelial cells from smokers (group B)
Number of subjects: 39
Study: 322491

Group type: COMPARATOR
Intervention: naproxen sodium (550 mg initial dose followed by 275 mg every six hours for a maximum of five days)
Number of subjects: 43

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 43
Study: 30898801

Group type: EXPERIMENTAL
Intervention: Enhanced LiFE (eLiFE) via smartphone application
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Adapted LiFE (aLiFE) via paper manuals
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group receiving international guidelines of physical activity
Number of subjects: 180
Study: 28924143

Group type: EXPERIMENTAL
Intervention: Fructooligosaccharides (FOS) 16g/day for 14 days
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Galactooligosaccharides (GOS) 16g/day for 14 days
Number of subjects: 35
Study: 25467017

Group type: EXPERIMENTAL
Intervention: Imetelstat (9.4 mg/kg on days 1 and 8 of a 21-day cycle)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Imetelstat
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Imetelstat (in patients with short telomere length)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Imetelstat (in patients with long telomere length)
Number of subjects: 116
Study: 23892298

Group type: EXPERIMENTAL
Intervention: Preoperative pulmonary rehabilitation programme (PRP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lobectomy only (Control Group S)
Number of subjects: 40
Study: 21820095

Group type: EXPERIMENTAL
Intervention: Successful CTO PCI in patients with DM
Number of subjects: 1742

Group type: EXPERIMENTAL
Intervention: Use of drug-eluting stents (DES) in patients with DM
Number of subjects: 1742

Group type: EXPERIMENTAL
Intervention: Use of drug-eluting stents (DES) in patients without DM
Number of subjects: 1742

Group type: EXPERIMENTAL
Intervention: Successful CTO PCI in patients without DM
Number of subjects: 1742
Study: 19428082

Group type: EXPERIMENTAL
Intervention: Suturing at the prostatic vesical junction (group 1)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Urethral catheter traction (group 2)
Number of subjects: 156
Study: 17527093

Group type: EXPERIMENTAL
Intervention: Nucleoside-sparing regimen (lopinavir/ritonavir at 533/133 mg twice a day and efavirenz at 600 mg/d)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Nucleoside-containing regimen (efavirenz and 2 nucleoside analogues)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz)
Number of subjects: 62
Study: 15103923

Group type: EXPERIMENTAL
Intervention: Local anesthesia with 5-ml dose of 1% lidocaine injected into the periprostatic nerve plexus at 3 minutes before the procedure
Number of subjects: 178

Group type: COMPARATOR
Intervention: No anesthesia (control group)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Local anesthesia with 5-ml dose of 1% lidocaine
Number of subjects: 178
Study: 11473488

Group type: EXPERIMENTAL
Intervention: Exercise (Ex)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Exercise + Hormone Replacement Therapy (ExHRT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (Co)
Number of subjects: 80
Study: 9711449

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Montelukast
Number of subjects: 0
Study: 7852181

Group type: EXPERIMENTAL
Intervention: Mammography
Number of subjects: 950

Group type: COMPARATOR
Intervention: Physical examination
Number of subjects: 950
Study: 3289850

Group type: EXPERIMENTAL
Intervention: Propionibacterium granulosum KP-45 (10 mg infusion for at least 3 days before operation)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propionibacterium granulosum KP-45
Number of subjects: 100
Study: 30221841

Group type: EXPERIMENTAL
Intervention: Treat-to-target (TTT) intervention
Number of subjects: 321
Study: 27737930

Group type: EXPERIMENTAL
Intervention: Lu AF09535
Number of subjects: 0
Study: 25548845

Group type: EXPERIMENTAL
Intervention: RT002 (injectable botulinum toxin type A)
Number of subjects: 48
Study: 23347858

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with bare-metal stents
Number of subjects: 220

Group type: COMPARATOR
Intervention: Minimally invasive direct coronary artery bypass surgery (MIDCAB)
Number of subjects: 220
Study: 21315003

Group type: EXPERIMENTAL
Intervention: Continuous blood purification (CBP) with continuous veno-venous hemofiltration (CVVH) for 72 hours, ultrafiltrate volume 40 ml×kg(‐1)×h(‐1)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (routine treatment according to international guidelines)
Number of subjects: 45
Study: 19720365

Group type: EXPERIMENTAL
Intervention: Live oral cholera vaccine 638 (2 x 10(9) CFU)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 18071169

Group type: EXPERIMENTAL
Intervention: Levomethadyl
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 165

Group type: COMPARATOR
Intervention: Buprenorphine
Number of subjects: 165
Study: 15376518

Group type: EXPERIMENTAL
Intervention: 100-microA, 20-s current pulses through deionized water
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100-microA, 20-s current pulses through saturated 20.4% NaCl solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100-microA, 20-s current pulses through 1% acetylcholine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100-microA, 20-s current pulses through 1% sodium nitroprusside
Number of subjects: 0
Study: 11575110

Group type: EXPERIMENTAL
Intervention: GTR and antibiotics (minocycline ointment locally, doxycycline and amoxyline systemically)
Number of subjects: 20

Group type: COMPARATOR
Intervention: GTR alone (control group)
Number of subjects: 20
Study: 9606770

Group type: EXPERIMENTAL
Intervention: Day-hospital rehabilitation (DHR)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (varied definitions)
Number of subjects: 15
Study: 7992907

Group type: COMPARATOR
Intervention: Fentanyl 0 micrograms.kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fentanyl 2 micrograms.kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fentanyl 4 micrograms.kg‐1
Number of subjects: 120
Study: 2563454

Group type: EXPERIMENTAL
Intervention: Exercise-induced hypoxic-reperfusion injury
Number of subjects: 0
Study: 9297

Group type: EXPERIMENTAL
Intervention: Clemastine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 30882524

Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural boluses (6-mL every 45 minutes with 0.1% ropivacaine and 2 microg/mL fentanyl)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Continuous epidural infusion (8 mL/h with 0.1% ropivacaine and 2 microg/mL fentanyl)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural boluses
Number of subjects: 120

Group type: COMPARATOR
Intervention: Continuous epidural infusion
Number of subjects: 120
Study: 31641199

Group type: EXPERIMENTAL
Intervention: Calibrated interdental brushes (IDBs) used daily on test sites.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no cleaning on control sites).
Number of subjects: 25
Study: 30569677

Group type: EXPERIMENTAL
Intervention: Minimally invasive osteotomy Ilizarov technique combined with intramedullary nail
Number of subjects: 71

Group type: COMPARATOR
Intervention: Simple Ilizarov technique
Number of subjects: 71
Study: 27241876

Group type: EXPERIMENTAL
Intervention: Telemedicine consultations
Number of subjects: 402

Group type: COMPARATOR
Intervention: Traditional specialist consultations
Number of subjects: 402
Study: 24717389

Group type: EXPERIMENTAL
Intervention: Usual care in the ZODIAC trial
Number of subjects: 18154

Group type: EXPERIMENTAL
Intervention: History of suicide attempts
Number of subjects: 18154

Group type: EXPERIMENTAL
Intervention: Usage of antidepressant medication
Number of subjects: 18154

Group type: EXPERIMENTAL
Intervention: History of > 5 hospitalizations in the past
Number of subjects: 18154
Study: 22515941

Group type: EXPERIMENTAL
Intervention: Low fat diet (20% total energy from long chain triglycerides)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Modified fat diet (20% from long chain triglycerides and 20% from medium chain triglycerides)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Normal fat diet (40% total energy from long chain triglycerides)
Number of subjects: 117
Study: 20574943

Group type: EXPERIMENTAL
Intervention: Stent graft
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balloon angioplasty (PTA)
Number of subjects: 0
Study: 17615257

Group type: EXPERIMENTAL
Intervention: TGFB1 gene polymorphisms (specifically high TGFB1 producer genotypes, ‐509TT and 10Pro/Pro)
Number of subjects: 754

Group type: EXPERIMENTAL
Intervention: TGFB1 gene polymorphisms (specifically ‐509TT)
Number of subjects: 754

Group type: EXPERIMENTAL
Intervention: Haplotype analysis under a recessive model
Number of subjects: 754

Group type: COMPARATOR
Intervention: Polymorphisms at codons 25 and 263
Number of subjects: 754
Study: 16131584

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (physical activity-behavior-diet-based) for 3 months
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (age-matched lean adolescents)
Number of subjects: 21
Study: 11999260

Group type: EXPERIMENTAL
Intervention: Brief intervention for hazardous alcohol use
Number of subjects: 16
Study: 10606193

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 650
Study: 7575696

Group type: EXPERIMENTAL
Intervention: Presence of rheumatoid factor
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Presence of damage at baseline
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Cumulative joint inflammation
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Continued joint inflammation
Number of subjects: 1
Study: 2405609

Group type: EXPERIMENTAL
Intervention: Aspirin and dipyridamole
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 7363436

Group type: EXPERIMENTAL
Intervention: Disopyramide (200 mg single dose)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg single dose)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Chronic disopyramide therapy (200 mg every 6 hours for 1 week)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Chronic propranolol therapy (80 mg every 8 hours for 1 week)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Concurrent administration of propranolol and disopyramide
Number of subjects: 16
Study: 31299857

Group type: EXPERIMENTAL
Intervention: PACAP27 (10 picomol/kg/min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PACAP27
Number of subjects: 20
Study: 31319363

Group type: EXPERIMENTAL
Intervention: Identifying one target in simulated traffic scenes
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Explicit instructions regarding the level of risk in Experiment 2
Number of subjects: 79
Study: 28723718

Group type: EXPERIMENTAL
Intervention: HMD group (head-mounted device-based gaming procedure)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: HMD group
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (vestibular rehabilitation only)
Number of subjects: 47
Study: 25498130

Group type: EXPERIMENTAL
Intervention: IDegAsp
Number of subjects: 424
Study: 23589670

Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 21342243

Group type: EXPERIMENTAL
Intervention: Self-monitoring-based disease management strategy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 62
Study: 19136753

Group type: EXPERIMENTAL
Intervention: Butorphanol (1, 1.5 and 2 mg based on body weight)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (intramuscular saline)
Number of subjects: 70
Study: 17197959

Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography followed by endoscopic papillotomy for bile duct stones (EEI)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Early conservative management (ECM)
Number of subjects: 103
Study: 15008829

Group type: EXPERIMENTAL
Intervention: New Zealand Diabetes Passport
Number of subjects: 398

Group type: COMPARATOR
Intervention: Control booklet
Number of subjects: 398
Study: 11464977

Group type: EXPERIMENTAL
Intervention: 60 mg/kg MSL-109
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: 15 mg/kg MSL-109
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: MSL-109 (60 mg and 15 mg combined) in D+/R- subgroup
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: MSL-109 (60 mg and 15 mg combined) in D+/R+ and D-/R+ subgroup
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: MSL-109
Number of subjects: 179
Study: 9766703

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for anterior MI (20 patients)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No exercise training for anterior MI (20 patients)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for inferior MI (15 patients)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No exercise training for inferior MI (15 patients)
Number of subjects: 70
Study: 8116724

Group type: EXPERIMENTAL
Intervention: Umbilical Doppler velocimetry
Number of subjects: 1598

Group type: COMPARATOR
Intervention: Control group (no Doppler velocimetry)
Number of subjects: 1598
Study: 3661492

Group type: EXPERIMENTAL
Intervention: Cisplatin chemotherapy (75‐100 mg/m2) and concomitant radiotherapy (20.00 Gy in 1 week) followed by full course (120 mg/m2 of cisplatin and 38.40 Gy of radiation)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Full course (FC) therapy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Partial course (PC) therapy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 50
Study: 31317668

Group type: EXPERIMENTAL
Intervention: Mepolizumab liquid formulation (100 mg) administered subcutaneously via prefilled syringe or autoinjector
Number of subjects: 244

Group type: COMPARATOR
Intervention: Lyophilized formulation of Mepolizumab
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: On-treatment adverse events
Number of subjects: 244
Study: 28103433

Group type: EXPERIMENTAL
Intervention: golimumab
Number of subjects: 68
Study: 27270245

Group type: EXPERIMENTAL
Intervention: Fish oil lipid emulsion (LE)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Soybean oil lipid emulsion (LE)
Number of subjects: 14
Study: 25513749

Group type: EXPERIMENTAL
Intervention: Experimental group (executive function training)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (easier, consistent-difficulty planning tasks)
Number of subjects: 55
Study: 23931876

Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 17269591

Group type: EXPERIMENTAL
Intervention: Contemporary treatment of gynecomastia
Number of subjects: 0
Study: 12511716

Group type: EXPERIMENTAL
Intervention: Self-management (SM)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 214
Study: 10357727

Group type: EXPERIMENTAL
Intervention: 120 mg orlistat 3 times daily
Number of subjects: 729

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 729
Study: 7589634

Group type: EXPERIMENTAL
Intervention: hMG and GH (4 IU)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: hMG and GH (12 IU)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: hMG and GH (24 IU)
Number of subjects: 64

Group type: COMPARATOR
Intervention: hMG and placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: hMG and GH (any dose)
Number of subjects: 64
Study: 1936001

Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7065664

Group type: EXPERIMENTAL
Intervention: 0.1% triamcinolone acetonide ointment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control preparation
Number of subjects: 15
Study: 30830077

Group type: EXPERIMENTAL
Intervention: Travoprost (0.004%) monotherapy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Travoprost (0.004%) added to timolol (0.5%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Travoprost (0.004%) added to dorzolamide (2%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Evening use of Travoprost
Number of subjects: 50
Study: 28856602

Group type: EXPERIMENTAL
Intervention: Orodispersible (OD) ticagrelor tablets (90 mg)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Immediate-release (IR) ticagrelor tablets
Number of subjects: 78
Study: 25247485

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (HD-DXM) with low-dose dexamethasone maintenance (HD-DXM-M group)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (HD-DXM) without low-dose dexamethasone maintenance (HD-DXM-nM group)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Prednisone (control group)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone with low-dose dexamethasone maintenance (HD-DXM-M group)
Number of subjects: 61
Study: 23460266

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0